01 (Image 01)
Nifedipine Tablet, Extended Release
Product Images NDC 71335-1721
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Nifedipine (NDC 71335-1721). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
02 (Image 02)
This is a table presenting the adverse effects reported for Nifedipine extended-release tablets as compared to placebo. The adverse effects reported are headache, fatigue, dizziness, constipation, and nausea. The percentage of participants who reported each side effect is provided for both the Nifedipine and placebo groups.*
03 (Image 03)
This is a table showing the percent of patients who experienced different adverse effects while taking Nifedipine Capsules versus Placebo. Adverse effects reported include dizziness, lightheadedness, giddiness, flushing, heat sensation, headache, weakness, nausea, heartburn, muscle cramps, tremor, peripheral edema, nervousness, mood changes, palpitations, dyspnea, cough, wheezing, nasal congestion, and sore throat.*
04 (Image 04)
Label (Lbl713351721)
This is a pharmaceutical label for a 60mg Tablet Procarbazine produced by Novast Laboratories. The label includes information on storage instructions, recommended temperature range, and cautions against keeping drugs out of the reach of children. Additionally, the label provides information on the drug's expiration date and its National Drug Code (NDC) number.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
